Justin Chakma's most recent trade in ARS Pharmaceuticals Inc was a trade of 274,100 Stock option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 274,100 | 274,100 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 12 Dec 2024 | 117,333 | 253,713 | - | 0.8 | 98,560 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2024 | 117,333 | 119,047 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.27 per share. | 12 Dec 2024 | 117,333 | 136,380 | - | 12.3 | 1,439,124 | Common Stock |
| ARS Pharmaceuticals Inc | Chakma Justin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.44 per share. | 12 Dec 2024 | 27,272 | 163,652 | - | 1.4 | 39,272 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 12 Dec 2024 | 27,272 | 136,380 | - | 12.1 | 328,969 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2024 | 27,272 | 55,461 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Chakma Justin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 10 Dec 2024 | 50,000 | 186,380 | - | 0.8 | 42,000 | Common Stock |
| ARS Pharmaceuticals Inc | Chakma Justin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.15 per share. | 10 Dec 2024 | 50,000 | 136,380 | - | 13.2 | 657,625 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 04 Dec 2024 | 50,000 | 136,380 | - | 14.2 | 711,615 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 04 Dec 2024 | 50,000 | 186,380 | - | 0.8 | 42,000 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 04 Dec 2024 | 49,640 | 186,020 | - | 0.8 | 41,698 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2024 | 49,640 | 100,000 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.13 per share. | 04 Dec 2024 | 49,640 | 136,380 | - | 14.1 | 701,642 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2024 | 45,000 | 149,640 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.95 per share. | 04 Dec 2024 | 45,000 | 136,380 | - | 14.0 | 627,944 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 04 Dec 2024 | 45,000 | 181,380 | - | 0.8 | 37,800 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 02 Dec 2024 | 45,000 | 181,380 | - | 0.8 | 37,800 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.67 per share. | 02 Dec 2024 | 45,000 | 136,380 | - | 13.7 | 615,218 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.19 per share. | 02 Dec 2024 | 45,000 | 136,380 | - | 13.2 | 593,402 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 45,000 | 3,260 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 02 Dec 2024 | 41,740 | 181,380 | - | 0.8 | 35,062 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 41,740 | 194,640 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 02 Dec 2024 | 3,260 | 139,640 | - | 0.8 | 2,738 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,260 | 0 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.05 per share. | 25 Nov 2024 | 42,186 | 161,380 | - | 14.0 | 592,570 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 25 Nov 2024 | 32,814 | 203,566 | - | 14.0 | 459,422 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.39 per share. | 25 Nov 2024 | 25,000 | 136,380 | - | 14.4 | 359,750 | Common Stock |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 350,000 | 350,000 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 165,000 | 165,000 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 236,380 | 236,380 | - | - | Common Stock | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 236,380 | 236,380 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 236,380 | 236,380 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 82,733 | 82,733 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 48,260 | 48,260 | - | - | Stock option (right to buy) |